A selective microRNA-based strategy inhibits restenosis while preserving endothelial function

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 4102-4114

  Santulli, Gaetano ^a   Wronska, Anetta ^a   Uryu, Kunihiro ^b   Diacovo, Thomas G ^a   Gao, Melanie ^a   Marx, Steven O ^a   Kitajewski, Jan ^a   Chilton, Jamie M ^c   Akat, Kemal Marc ^b   Tuschl, Thomas ^b   Marks, Andrew R ^a   Totary Jain, Hana ^a,c  

^a NewYork Presbyterian Hospital   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MICRORNA 126; MIRN126 MICRORNA, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HYPERCOAGULABILITY; IN VITRO STUDY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RAT; RESTENOSIS; TANDEM REPEAT; VASCULAR SMOOTH MUSCLE; ADENOVIRIDAE; ANIMAL; CELL CULTURE; CORONARY RESTENOSIS; CYTOLOGY; GENETICS; HUMAN; MALE; NEOINTIMA; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THROMBOPHILIA;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; CORONARY RESTENOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOTHELIAL CELLS; HUMANS; MALE; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; RATS; RATS, SPRAGUE-DAWLEY; THROMBOPHILIA;

EID: 84907007919     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76069     Document Type: Article

References (65)

1. Stefanini GG, Holmes DR, Holmes DR J.R. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3): 254-265.
2. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366(1): 54-63.
3. De Luca G, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patientlevel meta-analysis of randomized trials. Arch Intern Med. 2012;172(8): 611-621.
4. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res. 2013;99(2): 353-363.
5. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011;4(1): 104-111.
6. Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics. 2013;14(12): 1517-1526.
7. Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR. Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 2012;72(7): 1836-1843.
8. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. Circulation. 2001;103(24): 2967-2972.
9. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76(3): 412-417.
10. Marks AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med. 2003;349(14): 1307-1309.
11. Joner M, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5): 333-342.
12. Guagliumi G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv. 2012;5(1): 12-20.
13. Liu HT, et al. Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. Tex Heart Inst J. 2010;37(2): 194-201.
14. Cassese S, Kastrati A. New-generation drug-eluting stents for patients with myocardial infarction. JAM.A. 2012;308(8): 814-815.
15. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9(8): 439-453.
16. Otsuka F, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and Paclitaxel-eluting stents in humans. Circulation. 2014;129(2): 211-223.
17. Daemen J, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel- eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562): 667-678.
18. Ali ZA, et al. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013;6(5): 507-517.
19. Joner M, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1): 193-202.
20. Santulli G, et al. CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc. 2012;1(4): e001081.
21. Finn AV, Vorpahl M, Ladich E, Virmani R. Future directions in stenting. Expert Rev Cardiovasc Ther. 2010;8(1): 1-6.
22. Elia L, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009; 16(12): 1590-1598.
23. Cordes KR, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256): 705-710.
24. McDonald RA, et al. miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. Eur Heart J. 2013;34(22): 1636-1643.
25. Wang S, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2): 261-271.
26. Schober A, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4): 368-376.
27. Nichol D, Stuhlmann H. EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood. 2012;119(6): 1345-1352.
28. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med. 2006;12(5): 585-591.
29. Qiao C, et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. 2011;18(4): 403-410.
30. Fish JE, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2): 272-284.
31. Kelly EJ, Hadac EM, Greiner S, Russell SJ. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med. 2008; 14(11): 1278-1283.
32. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet. 2009;10(8): 578-585.
33. Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009;37(6): e43.
34. Iaccarino G, Smithwick LA, Lefkowitz RJ, Koch WJ. Targeting Gβ γ signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc Natl Acad Sci U S A. 1999;96(7): 3945-3950.
35. Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-κB-dependent hypertrophic gene expression. Hypertension. 2010; 56(4): 696-704.
36. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andres V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997;99(10): 2334-2341.
37. Tanner FC, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000;101(17): 2022-2025.
38. Moss SC, Lightell DJ, Lightell DJ Jr, Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem. 2010;285(16): 11991-11997.
39. Goukassian D, et al. Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J. 2001;15(11): 1877-1885.
40. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol. 2008;28(2): 223-232.
41. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59(23): 2051-2057.
42. Zhou J, et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res. 2013;113(1): 40-51.
43. Gonzalez P, et al. A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biol. 2004;2:5.
44. Boehm M, et al. Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism. J Clin Invest. 2004;114(3): 419-426.
45. Luscher TF, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8): 1051-1058.
46. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108(14): 1701-1706.
47. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol. 2010;55(15): 1553-1565.
48. Rossi ML, Zavalloni D, Gasparini GL, Mango R, Belli G, Presbitero P. The first report of late stent thrombosis leading to acute myocardial infarction in patient receiving the new endothelial progenitor cell capture stent. Int J Cardiol. 2010;141(1): e20-e22.
49. Akyurek LM, Boehm M, Olive M, Zhou AX, San H, Nabel EG. Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 2010;396(2): 359-363.
50. Indolfi C, et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell pro- liferation induced by vascular injury. Nat Med. 1997;3(7): 775-779.
51. Claudio PP, et al. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. Circ Res. 1999;85(11): 1032-1039.
52. Luo Z, Sata M, Nguyen T, Kaplan JM, Akita GY, Walsh K. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 1999;99(14): 1776-1779.
53. Lamfers ML, et al. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus- mediated gene transfer of the cell surfacedirected plasmin inhibitor ATF.BPTI. Gene Ther. 2001;8(7): 534-541.
54. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89(2): 133-138.
55. Kolandaivelu K, Leiden BB, Edelman ER. Predicting response to endovascular therapies: Dissecting the roles of local lesion complexity, systemic comorbidity, and clinical uncertainty. J Biomech. 2014;47(4): 908-921.
56. Kang SH, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35(17): 1147-1158.
57. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007; 4(9): 721-726.
58. Iaccarino G, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res. 2005;97(11): 1182-1189.
59. Totary-Jain H, et al. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J Biol Chem. 2013; 288(9): 6034-6044.
60. Ciccarelli M, et al. Endothelial α1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol. 2008;153(5): 936-946.
61. Sorriento D, et al. The G-protein-coupled receptor kinase 5 inhibits NFκB transcriptional activity by inducing nuclear accumulation of IκB α. Proc Natl Acad Sci U S A. 2008;105(46): 17818-17823.
62. Santulli G, et al. Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit. J Transl Med. 2011;9:7.
63. Doggett TA, et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(α)-vWF tether bond. Biophys J. 2002;83(1): 194-205.
64. Iaccarino G, et al. AKT participates in endothelial dysfunction in hypertension. Circulation. 2004;109(21): 2587-2593.
65. Santulli G, et al. In vivo properties of the proangiogenic peptide QK. J Transl Med. 2009;7:41.